Le Lézard
Classified in: Health
Subjects: SVY, HSP, BLK, TRI

A diabetes diagnosis later in life may signal early pancreatic cancer in African Americans and Latinos


LOS ANGELES, June 17, 2018 /PRNewswire-USNewswire/ -- Each year, more than one million Americans are diagnosed with adult-onset diabetes mellitus, also known as type 2 diabetes. The new diagnosis comes with a long list of potential complications: high blood pressure, nerve damage, kidney disease, stroke, glaucoma and more. But for African Americans and Latinos, a diagnosis of diabetes after age 50 may also come with a more than threefold risk for developing pancreatic cancer, according to a new study led by the Keck School of Medicine of USC published today in the Journal of the National Cancer Institute.

"There are very few studies on diabetes and pancreatic cancer that include Latinos and African Americans," says the study's lead author V. Wendy Setiawan, PhD, associate professor of preventive medicine at the Keck School. "Both groups have a high rate of diabetes, and African Americans, in particular, have a higher risk of developing pancreatic cancer relative to other racial/ethnic groups. Because most people with pancreatic cancer are diagnosed at a late stage, the five-year survival rate is low ? about 8 percent. Identifying people who are at high risk early on could potentially save their lives."

Symptoms of pancreatic cancer typically present when the disease is in its later stages, and no screening methods currently exist.

Using prospective data from approximately 49,000 African Americans and Latinos, the researchers found that people who were diagnosed with diabetes between the ages of 65 and 85 were more likely to develop pancreatic cancer within three years as compared with people without diabetes. The data showed that Latinos were four times more likely to develop pancreatic cancer within three years of a diabetes diagnosis, and African Americans were three times more likely.

The research team also looked at whether late-onset diabetes was associated with breast, prostate or colorectal cancer, and no association was found.

"What we found is that, yes, diabetes is associated with pancreatic cancer in African Americans and Latinos, but we also discovered that there is a different type of diabetes here, a late-onset diabetes that's associated with developing pancreatic cancer within 36 months. The evidence suggests that late-onset diabetes may be an early sign of pancreatic cancer," Setiawan says.

Late-onset diabetes may be a useful marker for pancreatic cancer, she adds, providing an opportunity to screen high-risk groups with new tools such as liquid biopsy, which is a test that looks for cancer cells or DNA from cancer cells in the blood.

"Pancreatic cancer is a rare disease, but if you are diagnosed with late-onset diabetes, have a conversation with your clinician about your individual risk," Setiawan says. "Early intervention could improve survival."

For more information about the Keck School of Medicine of USC, go to keck.usc.edu.

This study was supported by the National Institutes of Health under award numbers R01CA209798 and U01CA164973. Approximately 80 percent of the project's funding was federally funded. Twenty percent of the project's funding was not federally funded. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

SOURCE Keck School of Medicine of USC


These press releases may also interest you

at 16:35
DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring...

at 16:33
A bill named in memory of four-year-old Ana Lucía "Lulu" Haynes, who passed away from sepsis in 2014, has been reintroduced in the House of Representatives. It arrives ahead of next week's Pediatric Sepsis Week observance, which provides an annual...

at 16:30
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it will be presenting promising new preclinical data from its platform built (or optimized) to discover...

at 16:30
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, the Ontario Securities Commission (the...

at 16:30
Evolent Health, Inc. , a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial...

at 16:30
Canopy Growth Corporation ("Canopy Growth" or the "Company") announced today that in connection with the creation of the non-voting and non-participating exchangeable shares in the capital of Canopy Growth (the "Exchangeable Shares"), on...



News published on and distributed by: